Clinical Data Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 BioSpaceSales of Amgen's thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) BioSpace Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025. Clinical DataOphthalmologyRead full story Post navigation Previous: Amgen scores with new thyroid eye disease formulationNext: AI giant Anthropic buys Coefficient Bio for $400m Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026